Table 2.
Outcomes of clinical trials of CAR-NK cells presented at ASH 2022
| NCT number | Disease | Source | Target | Patient number | Preconditioning regimen | Cell dose (108) | Combination | ORR/CR | GVHD | CRS/ICANS | Abstract Number | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05008575 | AML | Umbilical cord-derived | CD33 | 10 | FC | 6, 12 and 18* | None | 60%/60% | None | Grade 2 CRS: 1 | 3317 | [11] |
| NCT05182073 | MM | iPSCs | BCMA | 6 | FC | 1 or 3 | None | 16.7%/0 | None | 2004 | [12] | |
| 3 | FC | 1 | Daratumumab | 66.7%/0 |
*Three patients received 3 rounds of CAR NK cells (6 × 108, 1.2 × 109 and 1.8 × 109 cells) with an interval of 7 days. Three patients received one dose of 1.8 × 109 CD33 CAR NK cells. In dose group three, four patients received 3 rounds of 1.8 × 109 CD33 CAR NK cells with an interval of 7 days
AML acute myeloid leukemia, FC fludarabine and cyclophosphamide, MM multiple myeloma, iPSCs induced pluripotent stem cells, CAR chimeric antigen receptor, CRS cytokine release syndrome, ORR overall response rete, CR complete response, ICANS immune effector cell-associated neurotoxicity syndrome